A
Apollomics
An innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies
About Apollomics
Apollomics is a biotechnology company focused on the discovery and development of oncology combination therapies. Operating in both the U.S. and China, the company leverages partnerships with other biotechnology firms to enhance its capabilities. Founded in 2015, Apollomics has built a pipeline of ten drug candidates across 12 programs, with five candidates at the clinical stage. The pipeline is categorized into three groups based on mechanisms of action: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Tumor inhibitors include small molecule inhibitors targeting uncontrolled growth signaling pathways, with a c-Met inhibitor as the core product. Anti-cancer enhancers are designed to boost the efficacy of other treatments and include antagonists developed as adjuncts to chemotherapy. Immuno-oncology drugs utilize the body's immune system to combat cancer, featuring mono-specific and bi-specific antibodies and a novel cancer vaccine. Apollomics aims to develop synergistic combination therapies to address unmet needs in cancer treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Foster City, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 72.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Alternative Medicine, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, SPAC Target, SPAC IPO Announced, DT and LS, UKSU
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2019
- Capital deployed
- $59M
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Mar 2026 | $2M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | May 2024 | $6M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Apollomics is 2.6K monthly website visits, up 0% over the last three months. Apollomics's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | 1 | $9.7M | $12M |
 GammaDelta TherapeuticsAllogeneic gamma-delta T-cell immunotherapies for cancer treatment |
London, United Kingdom | Acquired | |||
 Scenic BiotechGenetic modifier therapies for rare inherited diseases |
Amsterdam, Netherlands | Operational | |||
 SpyBiotechNovel vaccine platform using protein superglue technology |
Oxford, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 AvigenPreclinical selection platform for potent immune cells |
London, United Kingdom | Operational | |||
 BioCaptivaNovel liquid biopsy device for cancer diagnostics |
St Andrews, United Kingdom | Operational | |||
 Myricx BioNovel antibody-drug conjugate payloads for cancer treatment |
London, United Kingdom | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Series B and later3 investors entered at this stage
Ping An Capital
Ping An Group- MCMaxpro Capital Acquisition Corp
Other known investors1 additional known investor
University of Nottingham
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apollomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apollomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.